The Periodic Fever Market is estimated at US$775.3 million in 2026 and is projected to grow at a CAGR of 4.1% to reach US$1.06 billion by 2034.
Core applications include rare disease diagnosis, symptom control, long term inflammatory management, pediatric specialty care, and genetic counseling support, where buyers increasingly seek quality, reliability, and stronger functional fit. Demand remains supported by improved recognition of autoinflammatory disorders, better diagnostic pathways, specialist care expansion, and patient advocacy activity, encouraging continued portfolio development, service enhancement, and channel expansion.
This product will be delivered within 1-3 business days.
Market Overview
The Periodic Fever Market includes diagnostic, therapeutic, and supportive care solutions addressing recurrent fever syndromes and related autoinflammatory conditions. Its value chain spans diagnostic laboratories, pharmaceutical developers, specialist clinics, hospitals, genetic testing providers, and patient support networks.Core applications include rare disease diagnosis, symptom control, long term inflammatory management, pediatric specialty care, and genetic counseling support, where buyers increasingly seek quality, reliability, and stronger functional fit. Demand remains supported by improved recognition of autoinflammatory disorders, better diagnostic pathways, specialist care expansion, and patient advocacy activity, encouraging continued portfolio development, service enhancement, and channel expansion.
Key Companies Analysed
- Novartis
- Swedish Orphan Biovitrum
- Regeneron Pharmaceuticals
- Roche
- Sanofi
- Pfizer
- AstraZeneca
- Takeda
- AbbVie
- Boehringer Ingelheim
- Amgen
- Biogen
- Johnson & Johnson
- Bristol Myers Squibb
- Eli Lilly and Company
- GlaxoSmithKline
- Merck & Co.
- UCB
- Aytu BioPharma
- Sobi
Geographic Coverage
- North America - Market data and outlook to 2034
- United States
- Canada
- Mexico
- Europe - Market data and outlook to 2034
- Germany
- United Kingdom
- France
- Italy
- Spain
- Netherlands
- Switzerland
- Poland
- Sweden
- Russia
- Asia-Pacific - Market data and outlook to 2034
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Malaysia
- Vietnam
- Middle East and Africa - Market data and outlook to 2034
- Saudi Arabia
- South Africa
- Iran
- UAE
- Egypt
- South and Central America - Market data and outlook to 2034
- Brazil
- Argentina
- Chile
- Peru
Report Delivery and Support
- Updated PDF report and an MS Excel workbook containing market tables and figures.
- 7-day post-sale analyst support for clarifications and in-scope supplementary data.
- Complimentary report update covering the latest available data and relevant market developments.
This product will be delivered within 1-3 business days.
Table of Contents
1. Contents and Report Guide
2. Global Periodic Fever Market Overview
3. Periodic Fever Market Dynamics
4. Periodic Fever Market Strategic Analysis
5. Global Periodic Fever Market Size, Share and Forecast, 2025-2034
6. North America Periodic Fever Market Outlook to 2034
7. Europe Periodic Fever Market Outlook to 2034
8. Asia-Pacific Periodic Fever Market Outlook to 2034
9. Middle East and Africa Periodic Fever Market Outlook to 2034
10. South and Central America Periodic Fever Market Outlook to 2034
11. Periodic Fever Market Competitive Landscape
12. Appendix
Companies Mentioned
- Novartis
- Swedish Orphan Biovitrum
- Regeneron Pharmaceuticals
- Roche
- Sanofi
- Pfizer
- AstraZeneca
- Takeda
- AbbVie
- Boehringer Ingelheim
- Amgen
- Biogen
- Johnson & Johnson
- Bristol Myers Squibb
- Eli Lilly and Company
- GlaxoSmithKline
- Merck & Co.
- UCB
- Aytu BioPharma
- Sobi
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 160 |
| Published | October 2026 |
| Forecast Period | 2026 - 2034 |
| Estimated Market Value ( USD | $ 775.3 Million |
| Forecasted Market Value ( USD | $ 1069.2 Million |
| Compound Annual Growth Rate | 4.1% |
| Regions Covered | Global |
| No. of Companies Mentioned | 20 |
